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Efficacy of intramuscular and intraperitoneal deferoxamine for alumi.
num chelation. As intravenous administration of deferoxamine is dif-
ficult in home dialysis patients we set out to determine the efficacy of
intramuscular (i.m.) and intraperitoneal (i.p.) deferoxamine for removal
of aluminum. Patients with serum aluminum levels greater than 90
sg/liter were studied in a paired fashion with each patient serving as
their own control. Serum and peritoneal fluid aluminum were deter-
mined using flameless atomic absorption. In hemodialysis patients 2 g of
intravenous deferoxamine increased serum aluminum from 124.7
32.4 to 415 192.4 pg/liter. One g of deferoxamine given intrave-
nously or intramuscularly resulted in 76.8 35.3% and 70.4
23.2%, respectively, of the 2 g i.v. response. The rate at which serum
aluminum increased following i.v. deferoxamine infusion was biphasic,
with an initial rapid phase lasting 139 minutes followed by a much
slower phase, The volume of distribution of aluminum following
deferoxamine administration was 12,6 1.61 and the half life (t½) for
aluminum removal during hemodialysis was 9.0 2.0 hours. The
increase in serum aluminum following deferoxamine was not due to
chelation of erythrocyte aluminum as erythrocyte aluminum remained
constant over 24 hours. In patients on continuous ambulatory perito-
neal dialysis, 2 g intravenous deferoxamine resulted in the removal of
560 267 sg of aluminum over 24 hours while 2 g deferoxamine given
intraperitoneally gave 91 13% of the intravenous response. Alumi-
num clearance over 48 hours was twice that for 24 hours for both i.v.
and i.p. deferoxamine. These results indicate that aluminum is chelated
rapidly from tissues other than erythrocytes, and i.m. deferoxamine in
hemodialysis patients and i.p. deferoxamine in CAPD patients is as
efficacious and potentially safer than intravenously administered
deferoxamine.
Aluminum toxicity is an important clinical problem in pa-
tients with end—stage renal disease and has been associated with
encephalopathy [1, 2], osteomalacia [3, 4], and anemia [5].
Aluminum exposure comes primarily through aluminum con-
taining antacids [6, 7] or aluminum—contaminated dialysate
water [8]. Aluminum removal is difficult because of its large
volume of distribution and high protein binding [9]. Intravenous
deferoxamine (DFO), a trivalent metal chelating—agent, has
been used successfully to remove milligram quantities of alu-
minum during hemodialysis [3, 10—12]. Intravenous DFO, how-
ever, has the potential to cause hypotension even when admin-
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istered with a volumetric infusion pump [3, 12]. It is also our
policy not to allow self—administration of i.v. medications by
home dialysis patients. As data did not exist regarding the use
of alternative routes of DFO administration for aluminum
removal, the purpose of these studies was to determine the
efficacy of intramuscular (i.m.) and intraperitoneal (i.p.) DFO
for aluminum mobilization and removal. In addition, we also
compared the dose response to 1 and 2 g of DFO administered
intravenously.
Methods
Nine hemodialysis and six patients on continuous ambulatory
peritoneal dialysis (CAPD) (14 men and 1 woman) were studied
in a fashion allowing them to serve as their own controls. All
patients enrolled in these studies had initial serum aluminum
levels greater than 90 j,rg/liter. Three patients, however, had
initial levels measured at another laboratory and repeat values
done in this laboratory were less than 90 rg/liter. These patients
were not deleted from the study. DFO (Desferal, CIBA Phar-
maceutical Co., Summit, New Jersey, USA) in all studies, was
initially administered intravenously followed by either i.m. or
i.p. injections. All studies were separated by a minimum of two
weeks, and serum aluminum levels had always returned to
baseline pre-DFO values (117 68 vs. 107 pg/liter) prior
to initiating subsequent studies. In all hemodialysis and three of
six patients on CAPD, aluminum containing antacids were
discontinued prior to the studies.
Hemodialysis patients received DFO at the Denver V.A.
Dialysis Center midday the day after dialysis. Intravenous DFO
at doses of I and 2 g was administered to each patient at the rate
of 1 g/hr (15.1 2.6 mg/kg) using a volumetric infusion pump
(Imed Model 927, Imed Corp., San Diego, California, USA).
Blood was collected in heparinized tubes (green top) prior to the
infusion and at 0, 0.5, 1, 2, 3, 4 and 24 hours after the
completion of the 2 g DFO infusion. DFO (1 g) for i.m. injection
was mixed in 4 cc of bacterostatic water and 2 cc was injected
into each buttock midday the day after dialysis.
Patients on CAPD received 2 g (25.1 4.8 mg/kg) of DFO
i.v. midday using an infusion pump. All subsequent exchanges
over the next 36 to 48 hours were collected, the volume
measured and aluminum was quantitated as described below.
DFO (2 g) administered i.p. was mixed in 4 cc of bacterostatic
water, injected into the exchange bag just prior to the final
986
Aluminum chelation using i.m. and i.p. deferoxamine 987
exchange of the day. In all studies baseline peritoneal fluid was
collected prior to DFO administration and used to correct for
DFO-independent aluminum removal. DFO-independent alumi-
num removal per exchange averaged 10.7 4.9% (12.8 2.6
g) of the maximal DFO-induced aluminum removal, and was
similar in patients on or off aluminum—containing antacids (10.5
vs. 10.9%).
Analytical procedures
Plasma and peritoneal fluid aluminum levels were determined
using flameless atomic absorption as previously described [13].
Erythrocyte aluminum levels were determined using the follow-
ing procedure: whole blood was collected in a heparinized tube
and centrifuged for 10 minutes at 3000 g. Following removal of
plasma and buffy coat 10 ml of saline solution (140 mmollliter
NaCl, 5 mmollliter glycoglycine, pH 7.35) was used to wash the
erythrocytes. This solution was centrifuged at 3000 g for five
minutes and the supematant was removed. The washing pro-
cedure was repeated, care being taken to remove as much
supernatant as possible. Washed erythrocytes were mixed
vigorously, 0.5 ml was transferred to a plastic test tube and I ml
of trichloroacetic acid (TCA) solution (TCA 60 g/liter and
ascorbic acid 15 g!liter) was added while mixing. After standing
at room temperature for 10 minutes, the solution was centri-
fuged at 3000 g for 10 minutes and the resulting supernatant was
analyzed for aluminum as previously described [13].
To verify this technique several studies were conducted.
First, erythrocyte aluminum was quantitated in whole blood
stored at room temperature for three days and found to be
stable. Aluminum recovery from an erythrocyte TCA solution
following the addition of an aluminum standard was 98.2
3.4% (N = 8). Aluminum (200 gIliter) incubated with whole
blood for six hours did not alter baseline erythrocyte aluminum
levels (< 5 gIliter). Finally, erythrocyte aluminum levels ob-
tained from a 1:2 dilution with deionized water gave results
similar to the TCA method, but the TCA precipitation tech-
nique was more reproducible.
Calculations and statistical analysis
Non-DFO-dependent aluminum removal in peritoneal dialy-
sis patients was determined by measuring the aluminum content
(pg) of the exchange just prior to DFO administration. This was
then subtracted from all exchanges collected following DFO.
Twenty-four hours following a 2 g i.v. infusion of DFO, the
volume of distribution of aluminum and rate of removal during
hemodialysis was quantitated in five patients. In four patients a
Clirans Model TAF 08 (Terumo Corp., Tokyo, Japan) dialyzer
was used and a COBE PPD 1.6 m2 Parallel Plate (COBE
Laboratories, Lakewood, Colorado, USA) dialyzer was used in
the remaining patient. Blood flow was 250 mllmin in all except
one case when it was 200 ml/min. Predialysis and hourly (1 to 5
hr) arterial (predialyzer) and venous (post-dialyzer) plasma
samples were obtained for aluminum determinations. Semilog-
arithmic analysis of aluminum levels (sgIliter vs. time) revealed
a one component, first—order kinetic model with a mean r value
of 0.99 0.01. Aluminum removal during dialysis was calcu-
lated by multiplying the A-V difference X plasma flow X time.
The volume of distribution was calculated by dividing the
amount of aluminum removed during dialysis by the change in
the arterial Al concentration. The t'/2 for plasma aluminum
2
Time, hrs
Fig. 1. The change in plasma aluminum levels during and following the
i.v. infusion of two g of DFO. Breakpoint analysis [14] revealed a better
fit (P < 0.01) for a broken line with the breakpoint at 139 minutes. Data
are expressed as a percent of the 24 hour plasma aluminum level and
reported as the mean +SD, N = 6 or 7.
removal were calculated using standard, first-order kinetic
equations.
Data are expressed as the mean plus or minus one standard
deviation and were analyzed using the paired Student's t-test
unless otherwise noted.
Results
Figure 1 shows the increase in plasma aluminum during and
following a 2 g infusion of DFO over two hours. Data are shown
as a percent of the 24-hour level to eliminate interpatient
variation as the change in plasma aluminum varied between 300
and 800 p,g/liter for different subjects. The 24-hour plasma level
of aluminum following DFO administration was selected as
further increases with time have not been noted [3, 11]. In all
cases aluminum levels increased in a biphasic fashion with an
initial rapid increase during and shortly after the two hour
infusion followed by a second, much slower phase. Analysis of
individual data points using a statistical method for determining
the breakpoint of two lines [14] revealed two significantly
different slopes (P < 0.01) and a breakpoint occurring at 139
minutes (P < 0.01) after the infusion began. It is noteworthy
that after four hours plasma aluminum levels had attained 80%
of their 24-hour maximal value. In one patient, following 1 gram
of i.m. DFO, plasma aluminum levels rose to 28, 47, 74, and
87% of the 24 hour value at 2, 4, 8, and 12 hours, respectively.
Figure 2 shows the effect of DFO and subsequent hemodial-
ysis on plasma and erythrocytes aluminum levels. Plasma
aluminum increased following DFO administration and had a
volume of distribution of 12.7 1.6 liter (18.6 1.1% of body
wt). Hemodialysis produced a stable decline in plasma alumi-
num in individual patients with a t'/2 of 9.0 2.0 hours. There
was no obvious difference in the t'/2 between the TAF 08 and
PPD 1.6 M2 dialyzers, but decreasing the blood flow from 250 to
200 increased the t'/2 from 8.3 1.5 to 11.8 hours. In contrast,
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Fig. 2. Plasma (open symbols with dashed lines) and erythrocyte (closed
symbols with solid lines) aluminum levels prior to and following a 2 g
i.v. infusion of DFO, and during hemodialysis. Each pair of symbols
corresponds to the plasma and erythrocyte values from individual
patients.
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Fig. 5. Aluminum removal during consecutive exchanges following the
i.p. infusion of 2 g of DFO expressed as a percent of the maximum
value for individual CAPD patients. Values are the mean + SD, N = 6
for exchanges 1 to 5 and N = 3 for exchanges 6 to 9. AM refers to the
exchange following an overnight dwell.
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Fig. 3. The change in plasma aluminum levels in pg/liter following i.v.
or i.m. doses of DFO in individual patients studied with each patient
serving as their own control. Two g of DFO administered intravenously
was not statistically different (P> 0.05) than one g given either i.v. or
i.m.
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Fig. 4. Aluminum removal during consecutive exchanges following the
iv. infusion of2 g of DFO expressed as a percent of the maximum value
for individual CAPD patients. Values are the mean SD, N = 4 to 6.
AM refers to the exchange following an overnight dwell.
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Figure 3 shows the maximum change in plasma aluminum
following either i.v. or i.m. DFO administration. Two grams of
DFO given intravenously increased plasma aluminum levels to
415.3 192.4 p.g/liter. One gram of DFO administered i.v. or
i.m. resulted in an increment in plasma aluminum equivalent to
76.8 35.3 and 70.4 23.2%, respectively, of that achieved
with 2 g of i.v. Intramuscular DFO was, therefore, as effica-
cious as i.v. DFO for the mobilization of aluminum from body
stores. In addition, there appears to be little if any benefit from
the administration of 2 g of DFO, as the difference between 2 g
i.v. and either 1 g i.v. or i.m. did not reach statistical signifi-
cance (P> 0.05).
In peritoneal dialysis patients we first sought to determine the
kinetics of aluminum removal following one dose of i.v. or i.p.
DFO. In Figures 4 and 5, removals per exchange as a percent of
each individual patient's maximum—value are shown on the
ordinate, and the exchange number following either the i.v. or
i.p. infusion over a two day period is shown along the abscissa.
Following i.v. infusion (Fig. 4) there was a gradual increase in
aluminum removal until the fourth exchange, at which time it
remained relatively constant for at least the next 24 hours. In
Figure 5, removal of aluminum following DFO administered i.p.
is shown. Aluminum removal was near maximum following the
erythrocyte aluminum levels were not altered by either DFO
infusion or subsequent hemodialysis. Four additional patients
had erythrocyte aluminum levels determined prior to and 24
hours following the infusion of 2 g of DFO. For the seven
patients taken together, there was again no change in erythro-
cyte aluminum as post-DFO infusion values were 96.7 8.7%
of control values. It therefore seems that aluminum mobilized
by DFO and removed during dialysis comes from non-eryth-
rocyte sources.
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Fig. 6. Aluminum removal in patients on CAPD following 2 g of DFO
infused either i.v. or i.p. A shows aluminum removal (tg) during the
first 24 hours following the administration of DFO. B shows aluminum
removal (sg) for the first 48 hours following the infusion of DFO. Data
pairs for individual patients are connected by solid lines.
first exchange, and thereafter remained relatively constant
except following the overnight dwell when it increased to the
maximum value in all patients. Aluminum removal following
both i.v. and i.p. DFO was maximal or near maximal following
overnight dwells.
Figure 6 shows total aluminum removal for 24 and 48 hours
following either 2 g of DFO given intravenously or intraperito-
neally in patients on CAPD. Although aluminum removal varied
widely from patient to patient, peritoneal DFO was as efficacious
as intravenous for aluminum removal for both 24 (Fig. 6A) and
48 (Fig. 6B) hours following administration. During 24 hours
following i.v. administration 560.1 267.5 g of aluminum
were removed. Intraperitoneal infusion resulted in 91.4
13% of this value. During the 48-hour removal study 1,134
890.9 were removed following the intravenous dose, while
93.3 13.4% of this value was removed using i.p. DFO. It
should also be noted the 48-hour i.v. and i.p. clearance of
aluminum were 204% and 196% of the 24 hour doses, respec-
tively. It therefore seems that both i.v. and i.p. DFO elicit a
constant response in aluminum removal in CAPD patients for at
least 48 hours.
Finally, we determined if aluminum removal post-DFO and
initial plasma aluminum levels in patients on CAPD were
related. As shown in Figure 7, a strong correlation existed
(r = 0.97, P <0.01) is the six patients studied.
Discussion
Removal of excess aluminum in patients with end—stage renal
disease has become clinically important. Several recent studies
have documented reversal of ostemomalacia [10], anemia [5]
and encephalopathy [15] following aluminum removal. In these
studies DFO was administered intravenously, and to date very
little information exists regarding the use of alternative routes
of DFO administration to affect aluminum mobilization and
removal. Data does, however, exist regarding iron removal
following i.p. peritoneal and subcutaneous DFO administration.
Subcutaneous DFO is 90% as effective for iron removal as a
continuous i.v. infusion [16]. Falk et al [17] showed that i.p.
DFO in patients on CAPD was more effective than i.v. DFO in
hemodialysis patients for removing iron. Their data also suggest
DFO administered i.p. enters plasma.
The present studies indicate that both i.m. and i.p. DFO can
effect aluminum mobilization and removal. In hemodialysis
patients equal amounts of DFO administered i.m. or i.v. re-
sulted in equal aluminum mobilization. In CAPD patients i.p.
DFO was as effective as i.v. DFO for aluminum removal. In
addition, both i.v. and i.p. DFO resulted in prolonged aluminum
removal with equal amounts of aluminum being removed during
the first and second 24-hour periods.
The present studies also provide data regarding the dosage
and dosing interval of DFO which should be used for treating
both hemodialysis and CAPD patients. The dose of DFO used
by other investigators has varied from 28.5 mg/kg per dialysis
[10] to 6 g once weekly [15]. However, a high incidence of
side—effects has been reported with the latter dose [15, 18] and
most investigators have since been using 40 mg/kg or 2 g per
dialysis [3, 10]. In the present study the effect of 1 and 2 g of
DFO given intravenously did not differ statistically. This is in
agreement with Ciancionia et al [11] who also found no statis-
tical difference in plasma aluminum levels following a 1 or 2 g
dose of DFO. Whether the lack of a difference between 1 and 2
g dose of DFO holds when DFO is administered during hemo-
dialysis was not determined in this or the previous study [11].
As DFO has been reported to be cleared during hemodialysis
[19] administration of DFO during dialysis may reduce the
effective dose. Following DFO administration, removal of
plasma aluminum by hemodialysis occurred from one pool with
an apparent volume of distribution of 12.7 liter or 18.6% of total
body weight. Removal was slow with a t of nine hours, and
therefore less than 30% of the available chelated aluminum can
be removed during a four hour dialysis. In our patients
26.4 6.6% of the available aluminum was removed during
four hours of dialysis. These data are in close agreement with
Milliner et al [20] who showed DFO increased dialyzer clear-
ance of aluminum from 4.3 to 23.4 mllmin and that 33.6% of
plasma aluminum was removed during four hours of
hemodialysis. In light of these findings perhaps the frequency of
DFO administration to hemodialysis patients should not be
greater than every other dialysis. Likewise, for CAPD patients,
the prolonged duration of response to both i.v. and i.p. DFO
suggests that dosing interval should not be more frequent than
every second or third day. The ideal dose of DFO for patients
on CAPD was not evaluated in this study. The data, however,
suggest that the pool of aluminum available for chelation and
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Fig. 7. The correlation between initial plasma aluminum levels and
aluminum removal over 24 hours following the i.v. infusion of 2 g of
DFO in patients on CAPD. The correlation was 0.97 (P < 0.01). PPB is
equivalent to sg/liter.
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not the amount of DFO given was rate limiting, as aluminum
removal correlated highly with initial plasma levels even in
patients with extremely high, total body burdens of aluminum.
Furthermore, the individual with the highest plasma aluminum
level also had identical aluminum removal during the first and
second 24-hour clearance periods, which is in agreement with a
preliminary report by Hercy et al [21].
The kinetics of aluminum mobilization and a potential source
of the chelatable aluminum were investigated. Two distinctly
different slopes of aluminum mobilization into the plasma
following DFO administration were found, suggesting different
pools of chelatable aluminum exist. The rapid increase in
plasma aluminum during and shortly following the infusion
period could represent a readily chelatable pool. The second
slower rate of rise would then be due to aluminum removal from
sites more resistant to chelation. This hypothesis is consistent
with data from both Ciacioni et al [11] and Milliner et al [3]. The
increase in serum aluminum following DFO was not due to
chelation of erythrocyte aluminum as these levels were un-
changed by either DFO or hemodialysis. We have also been
unsuccessful in either loading or removing aluminum from
erythrocytes in vitro (unpublished results). It, therefore, seems
the aluminum present in erythrocyte is refractory to DFO
chelation.
Finally, although the literature is replete with articles docu-
menting the usefulness of DFO in treating aluminum intoxica-
tion in dialysis patients [5, 10, 15], the indications for treatment
have not been firmly established. Perhaps the large double—
blinded, multi-center study supported by CIBA—GEIGY and
scheduled to be completed by the end of 1986 may better define
the indications for and efficacy of DFO therapy. However,
since DFO is currently being given to a large number of dialysis
patients irrespective of its proven usefulness, its potential
toxicity is a relevant topic. Hypotension and ocular toxicity
have been related both to the dose and rate of i.v. administra-
tion of DFO [12, 22]. Recently it was shown that DFO given
during dialysis serves to aggravate the symptomatology of
dialysis encephalopathy [12, 15]. It has previously been shown
that dialysis in itself both initiates and precipitates the symp-
toms of dialysis encephalopathy [2]. Thus i.v. DFO therapy
administered during dialysis to patients suffering dialysis en-
cephalopathy may compound the adverse effect of dialysis on
this syndrome. In addition, certain bacteria [23] and possibly
fungi use DFO-Fe complex as a growth—promoting factor
which can cause serious and at times fatal infections. Because
of these adverse effects of DFO the smallest dose with clinical
efficiency, given in the interdialytic period with the shortest
interval between administration and removal may be advanta-
geous. The i.m. administration of this compound seems to have
all of the advantages cited above. First, it can be given in the
interdialytic period by the patient and this mode of administra-
tion has not been found to cause hypotension. Moreover, as
stated above, there are reasons to believe that the administra-
tion of DFO between dialyses is less likely to aggravate the
symptoms of dialysis encephalopathy. One g of DFO, which
has been found to be clinically as effective as 2 g [24] for the
treatment of aluminum—induced bone disease, can be given i.m.
12 hours prior to dialysis with similar capacity for chelation as
2 g of DFO administered i.v. during dialysis 48 hours prior to its
subsequent removal. The lower dose and shorter duration
between the i.m. administration of DFO and its removal by
dialysis reduces the patient's exposure to large and prolonged
circulating levels of DFO-Fe and DFO-A1 complexes, and may
minimize both the risk of infection and aggravation of dialysis
encephalopathy symptoms.
Both i.m. and i.p. DFO were found to be safe, although
long—term studies will be required. Intramuscular injections are
not without potential complications; in hemodialysis patients it
can lead to hematomas. We have not noted any hematomas in
our treated patients, although some discomfort during the
injection has been noted. No patient, however, has discontin-
ued therapy, and all i.m. injections were given on interdialytic
days. The safety of i.p. DFO is in agreement with Falk et al [17],
who also showed clearances of creatinine were unchanged
following i.p. DFO in CAPD patients [17].
In summary, the present studies showed i.m. and i.p. DFO
are as efficacious as i.v. DFO for aluminum mobilization and
removal. In addition, convenience, cost containment, and po-
tentially fewer side—effects make use of intramuscular and
intraperitoneal DFO in hemodialysis and peritoneal patients,
respectively, useful therapy for removal of excess aluminum.
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